Stephen D Lawn1, M Estée Török, Robin Wood. 1. The Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. sarah.walker@ctu.mrc.ac.uk
Abstract
PURPOSE OF REVIEW: We review recently published literature concerning the optimum time to start antiretroviral therapy (ART) in patients with HIV-associated opportunistic infections. RECENT FINDINGS: In addition to data from observational studies, results from six randomized controlled clinical trials were available by July 2010. The collective findings of these trials were that patients with CD4 cell counts less than 200 cells/μl who start ART within the first 2 weeks of treatment for opportunistic infections including Pneumocystis jirovecii pneumonia, serious bacterial infections or pulmonary tuberculosis have lower mortality when compared to patients starting ART at later time-points. Moreover, patients with pulmonary tuberculosis and CD4 counts of 200-500 cells/μl who started ART during tuberculosis (TB) treatment had improved survival compared to those who deferred ART until after the end of treatment. In contrast, in two separate studies, immediate ART conferred no survival benefit in patients with TB meningitis and was associated with substantially higher mortality risk in patients with cryptococcal meningitis. SUMMARY: Initiation of ART during the first 2 weeks of treatment for serious opportunistic infections has been shown to be associated with improved survival with the exception of patients with tuberculous meningitis and cryptococcal meningitis. Further clinical trials are ongoing.
PURPOSE OF REVIEW: We review recently published literature concerning the optimum time to start antiretroviral therapy (ART) in patients with HIV-associated opportunistic infections. RECENT FINDINGS: In addition to data from observational studies, results from six randomized controlled clinical trials were available by July 2010. The collective findings of these trials were that patients with CD4 cell counts less than 200 cells/μl who start ART within the first 2 weeks of treatment for opportunistic infections including Pneumocystis jirovecii pneumonia, serious bacterial infections or pulmonary tuberculosis have lower mortality when compared to patients starting ART at later time-points. Moreover, patients with pulmonary tuberculosis and CD4 counts of 200-500 cells/μl who started ART during tuberculosis (TB) treatment had improved survival compared to those who deferred ART until after the end of treatment. In contrast, in two separate studies, immediate ART conferred no survival benefit in patients with TB meningitis and was associated with substantially higher mortality risk in patients with cryptococcal meningitis. SUMMARY: Initiation of ART during the first 2 weeks of treatment for serious opportunistic infections has been shown to be associated with improved survival with the exception of patients with tuberculous meningitis and cryptococcal meningitis. Further clinical trials are ongoing.
Authors: Gillian L Dean; Simon G Edwards; Natalie J Ives; Gail Matthews; Emma F Fox; Lesley Navaratne; Martin Fisher; Graham P Taylor; Rob Miller; Chris B Taylor; Annemiek de Ruiter; Anton L Pozniak Journal: AIDS Date: 2002-01-04 Impact factor: 4.177
Authors: Marcel Yotebieng; Annelies Van Rie; Harry Moultrie; Stephen R Cole; Adaora Adimora; Frieda Behets; Tammy Meyers Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: Payam Nahid; Leah C Gonzalez; Irina Rudoy; Bouke C de Jong; Alon Unger; L Masae Kawamura; Dennis H Osmond; Philip C Hopewell; Charles L Daley Journal: Am J Respir Crit Care Med Date: 2007-02-08 Impact factor: 21.405
Authors: Azure T Makadzange; Chiratidzo E Ndhlovu; Kudakwashe Takarinda; Michael Reid; Magna Kurangwa; Philimon Gona; James G Hakim Journal: Clin Infect Dis Date: 2010-06-01 Impact factor: 9.079
Authors: Humphrey J Shao; John A Crump; Habib O Ramadhani; Leonard O Uiso; Sendui Ole-Nguyaine; Andrew M Moon; Rehema A Kiwera; Christopher W Woods; John F Shao; John A Bartlett; Nathan M Thielman Journal: AIDS Res Hum Retroviruses Date: 2009-12 Impact factor: 2.205
Authors: Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow Journal: PLoS One Date: 2009-05-18 Impact factor: 3.240
Authors: Thuli Mthiyane; Alex Pym; Keertan Dheda; Roxana Rustomjee; T Reddy; Shamila Manie Journal: Qual Life Res Date: 2016-06-09 Impact factor: 4.147
Authors: Stephen D Lawn; Lucy Campbell; Richard Kaplan; Andrew Boulle; Morna Cornell; Bernhard Kerschberger; Carl Morrow; Francesca Little; Matthias Egger; Robin Wood Journal: J Acquir Immune Defic Syndr Date: 2011-06-01 Impact factor: 3.731
Authors: Stephen D Lawn; Anthony D Harries; Graeme Meintjes; Haileyesus Getahun; Diane V Havlir; Robin Wood Journal: AIDS Date: 2012-11-13 Impact factor: 4.177
Authors: Emily W Bratton; Nada El Husseini; Cody A Chastain; Michael S Lee; Charles Poole; Til Stürmer; Jonathan J Juliano; David J Weber; John R Perfect Journal: PLoS One Date: 2012-08-24 Impact factor: 3.240
Authors: Monique van Lettow; Ann Åkesson; Alexandra L C Martiniuk; Andrew Ramsay; Adrienne K Chan; Suzanne T Anderson; Anthony D Harries; Elizabeth Corbett; Robert S Heyderman; Rony Zachariah; Richard A Bedell Journal: PLoS One Date: 2012-11-19 Impact factor: 3.240